SCHEMBL7723911

SCHEMBL7723911

O=C(NCc1ccncc1)N(CCO)CCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.56
ALDH1A1 P00352 3/20 0.52
GAA P10253 1/20 0.52
MAPT P10636 1/20 0.52
LMNA P02545 2/20 0.48
HTT P42858 3/20 0.48
CYP3A4 P08684 3/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
MMP13 P45452 2/20 0.46
MAPK14 Q16539 1/20 0.46
ROCK2 O75116 2/20 0.46
ROCK1 Q13464 2/20 0.46
RPS6KA5 O75582 1/20 0.46
MAP4K4 O95819 1/20 0.46
PRKCG P05129 1/20 0.46
PRKACA P17612 1/20 0.46
RPS6KB1 P23443 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7724193 0.90 SMN1; SMN2 (0.56) SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2D6
SCHEMBL7724191 0.88 KDM4E (0.50) SMN1; SMN2GAACYP3A4CYP1A2CYP2D6
SCHEMBL7723854 0.87 CYP1A2 (0.59) SMN1; SMN2ALDH1A1MAPTLMNAHTT
SCHEMBL7719562 0.83 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1GAAMAPTLMNA
SCHEMBL7723042 0.83 SMN1; SMN2 (0.51) SMN1; SMN2GAACYP1A2CYP2D6CYP2C9
SCHEMBL7719685 0.82 KDM4E (0.42) SMN1; SMN2ALDH1A1GAACYP3A4CYP1A2
Hydrochloric Acid SCHEMBL7729370 0.82 SMN1; SMN2 (0.48) SMN1; SMN2ALDH1A1GAAMAPTLMNA
SCHEMBL7719663 0.82 HPGD (0.59) SMN1; SMN2ALDH1A1GAAMAPTLMNA
SCHEMBL7724999 0.79 LMNA (0.49) SMN1; SMN2ALDH1A1GAAMAPTLMNA
SCHEMBL7719608 0.79 RAB9A (0.54) SMN1; SMN2ALDH1A1CYP3A4CYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6420398-B2 FOR TREATING AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS; 4-(3-(2-(ACETYLTHIO)ETHYL)-3-(2-CYCLOHEXYLETHYL)-UREIDOMETHYL)-1 -METHYLPYRIDINIUM IODIDE, FOR EXAMPLE; INHIBIT PRODUCTION OF TUMOR NECROSIS FACTOR ALPHA (TNF-A) SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US disclosed
US-20010041725-A1 Novel urea derivatives having nitrogen aromatic heterocycle SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-11-15 US disclosed
EP-1103543-A1 NOVEL UREA DERIVATIVES BEARING NITROGENOUS AROMATIC HETEROCYCLES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041725-A1 Novel urea derivatives having nitrogen aromatic heterocycle TNF, UACA, HRH4 SMN1; SMN2 4609/4885ALDH1A1 988/4885GAA 3471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.